Nutex Investments PLC (NUTEX) fair value: what the stock is really worth
We calculate from audited financials what Nutex Investments PLC is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Nutex Investments PLC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
NUTEX Investments Public Limited Company provides health preserving, health promotion, nutritional supplement, and cosmetic products in Hungary and internationally. It also engages in asset management.
Show more
NUTEX Investments Public Limited Company provides health preserving, health promotion, nutritional supplement, and cosmetic products in Hungary and internationally. It also engages in asset management. The company was formerly known as HUMET Trade, Research and Development Public Limited Company and changed its name to NUTEX Investments Public Limited Company in February 2011. The company was incorporated in 1996 and is based in Budapest, Hungary.
Stock analysis
Nutex Investments PLC (NUTEX) currently trades at 12.00 HUF, while our model-based Fair Value estimate is 27.76 HUF, implying the stock looks roughly 56.8% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 47.96 HUF per share, and 14 of the 15 models we run sit above the 12.00 HUF price.
Bear case: the Multiples group reads lowest at 13.19 HUF, and 1 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: 25.20 HUF (bear) to 32.73 HUF (bull), the price of 12.00 HUF sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Nutex Investments PLC reported revenue of 450K HUF in FY2025 versus 450K HUF in FY2021, a compound +0.0%/yr. Reported net income was 494M HUF in FY2025, compounding +149.8%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 2.1B HUF (≈ $6.6M) · P/E ratio 3.5 · EPS (TTM) 3.40 HUF · Net margin 109,816% · Return on equity 9.4% · Return on assets (EBIT) −1.0% · Operating margin 7,323% · Revenue (TTM) 450K HUF.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 33% below its 52-week high, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −17% fair-value upside, at 131%, NUTEX screens cheaper than that median.
Fair Value models
Bear 25.20 HUFFair Value 27.76 HUFBull 32.73 HUF
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (1.14 HUF per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.0%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−27.1%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in HUF (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in HUF: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+81.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+81.3%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−3,910% → −24,098%
2025 sits 229% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
⚠ Revenue per share shrinking 29.7%/yr over ~5Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 612 stocks
Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score68 · Top 25%
Profitability
Return on equity (TTM)9% · Above median
Return on assets−1% · Bottom 25%
Growth and dividend
Revenue growth0% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Nutex Investments PLC (NUTEX) overvalued or undervalued?
As of Sep 14, 2026, our model estimates a fair value of 27.76 HUF versus a price of 12.00 HUF, about +131% upside (undervalued).
What is the fair value of NUTEX?
Our model-based fair value for Nutex Investments PLC is 27.76 HUF (as of Sep 14, 2026), built from audited fundamentals. The current price: 12.00 HUF.
What is the quality score of NUTEX?
Nutex Investments PLC has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nutex Investments PLC (NUTEX)?
Our model-based price target is the fair value of 27.76 HUF (as of Sep 14, 2026) from 15 valuation models. Cautious scenario 25.20 HUF, optimistic scenario 32.73 HUF. It is a calculation from audited fundamentals, not an analyst target.
What is the Nutex Investments PLC stock forecast for 2026?
Our models put fair value at 27.76 HUF, about +131% upside versus a price of 12.00 HUF (undervalued). Cautious scenario 25.20 HUF, optimistic scenario 32.73 HUF. The calculation is refreshed regularly with new filings.
What is the revenue of Nutex Investments PLC (NUTEX)?
Nutex Investments PLC reported trailing-twelve-month revenue of about 450K HUF (latest available figure, as of Sep 14, 2026).
What growth is priced into Nutex Investments PLC (NUTEX)?
For today's price to be fair in a discounted-cash-flow model, Nutex Investments PLC would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.0 % per year. As of Sep 14, 2026.
What discount rate (WACC) does the fair value of NUTEX use?
Our models discount Nutex Investments PLC at 11.9 %: a base by market capitalisation (nano), damped by beta 0.97, country premium for Hungary. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Nutex Investments PLC that is less than minus 40 % per year a year over ten years, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Nutex Investments PLC (NUTEX) delivered so far?
Over the past 5 years revenue at Nutex Investments PLC grew +0.0 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Nutex Investments PLC (NUTEX) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Nutex Investments PLC (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Nutex Investments PLC (NUTEX)?
The free-cash-flow yield on the price is 16.39 %: that much free cash flow Nutex Investments PLC produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Nutex Investments PLC (NUTEX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nutex Investments PLC it is 27.76 HUF per share (as of Sep 14, 2026), against a price of 12.00 HUF. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Nutex Investments PLC stock overvalued or undervalued in 2026?
As of Sep 14, 2026, NUTEX trades below its calculated fair value: price 12.00 HUF, fair value 27.76 HUF, a gap of about +131% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NUTEX?
No. The price is what the market pays today (12.00 HUF); the fair value is what the company's own numbers justify (27.76 HUF). For Nutex Investments PLC the two are 15.76 HUF per share apart. That gap is exactly why we show both numbers side by side.
How much is Nutex Investments PLC worth?
The market values Nutex Investments PLC at about 2.1B HUF (market capitalisation, as of Sep 14, 2026). Per share that is 12.00 HUF; our models calculate a fair value of 27.76 HUF per share.
What do the bullish and bearish scenarios say about NUTEX?
Our models span a range for Nutex Investments PLC: cautious scenario 25.20 HUF, base 27.76 HUF, optimistic 32.73 HUF per share (as of Sep 14, 2026, price 12.00 HUF). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NUTEX?
Nutex Investments PLC trades at a price-to-earnings ratio of 3.5 (as of Sep 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 27.76 HUF is built from several models across several years. Other multiples: P/S 15.8.
How solid is the balance sheet of Nutex Investments PLC (NUTEX)?
Balance-sheet figures for Nutex Investments PLC (as of Sep 14, 2026): return on equity 9.4%. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is NUTEX from its 52-week high?
Nutex Investments PLC trades at 12.00 HUF, about 33% below its 52-week high of 17.85 HUF (as of Sep 14, 2026). Distance from the high says nothing about value: that is what the fair value of 27.76 HUF is for.
Which stocks are comparable to Nutex Investments PLC?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nutex Investments PLC stock attractive at the current price?
The data as of Sep 14, 2026: price 12.00 HUF, calculated fair value 27.76 HUF (+131%), Quality Score 68/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NUTEX calculated?
We run Nutex Investments PLC through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 27.76 HUF, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Nutex Investments PLC currently trades 131 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Nutex Investments PLC right now?
The price is below even our cautious bear case (25.20 HUF). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (68/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Nutex Investments PLC
How large is the market capitalisation of Nutex Investments PLC (NUTEX)?
The market capitalisation of Nutex Investments PLC is 2.1B HUF (≈ $6.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Nutex Investments PLC (NUTEX)?
Earnings per share at Nutex Investments PLC are 3.40 HUF (price ÷ EPS = P/E 3.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Nutex Investments PLC (NUTEX)?
The net margin of Nutex Investments PLC is 109,816% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nutex Investments PLC (NUTEX)?
The return on equity (ROE) of Nutex Investments PLC is 9.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nutex Investments PLC (NUTEX)?
On an EBIT basis the return on assets of Nutex Investments PLC is −1.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nutex Investments PLC (NUTEX)?
The operating margin of Nutex Investments PLC is 7,323% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at Nutex Investments PLC (NUTEX)?
Earnings per share at Nutex Investments PLC are growing +124% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Nutex Investments PLC in the live analysis
One click puts Nutex Investments PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
